Critic at Large

» funding and disease/medicine

Most Recent

image: Cancer Clinical Trials of Tomorrow

Cancer Clinical Trials of Tomorrow

By | April 1, 2013

Advances in genomics and cancer biology will alter the design of human cancer studies.

0 Comments

image: Genomics-Informed Pathology

Genomics-Informed Pathology

By | January 1, 2013

Twenty-first century lab reports will include test results read by a new breed of pathologist.

1 Comment

image: Medicines for the World

Medicines for the World

By | October 1, 2012

A global R&D treaty could boost innovation and improve the health of the world’s poor—and rich.

0 Comments

image: Polypharmacy

Polypharmacy

By | July 1, 2012

Dietary supplements can have serious side effects when mixed with prescription drugs, but not all herb-drug interactions are bad.

14 Comments

image: Food for Thought

Food for Thought

By | June 1, 2012

Plant research remains grossly underfunded, despite the demand for increased crop production to support a growing population.

6 Comments

image: Regulations for Biosimilars

Regulations for Biosimilars

By | June 1, 2012

As biologic drug patents begin to expire, generic versions will hit the market—but how will they be regulated?

2 Comments

image: Antibiotics in the Animals We Eat

Antibiotics in the Animals We Eat

By | April 1, 2012

Low-dose antibiotics in animal feed fuel drug-resistance in human infectious diseases.

0 Comments

image: Toads

Toads

By | August 1, 2011

Ascribing benefits to the experience of devastating illness or trauma is fraught with hidden dangers.

33 Comments

image: Hard and Harder

Hard and Harder

By | June 5, 2011

The path to eradicating malaria in Africa involves much more than just a vaccine.

18 Comments

image: Imagining a Cure

Imagining a Cure

By | April 11, 2011

For cancer patients, close is not good enough.

0 Comments

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham